Registry for adolescents with severe alopecia areata

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry focuses on adolescents aged 12-17 diagnosed with severe alopecia areata who are receiving routine care from dermatology providers. The study aims to evaluate the long-term safety and effectiveness of treatments for severe alopecia areata through standardized data collection, including patient-reported and clinician-reported outcomes. Data gathered will help characterize the disease's natural history, assess medication effectiveness and safety, and inform clinical decision-making. The registry will also track comorbidities, adverse events, and medication utilization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

To be eligible to participate in this registry, an individual must meet all the following criteria:

1. Has ever been diagnosed with severe AA by a dermatologist or a qualified healthcare provider.
2. Is 12-17 years of age at the time of enrollment.
3. Is willing to provide consent/assent for participation in the registry.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in the registry:

1. Is participating or planning to participate in a blinded clinical trial for any investigational medication.
2. Is unwilling or unable to provide standing height measurements.

Where it's running

• CorEvitas, LLC
  Waltham, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: CorEvitas

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata

  This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07803874

• VC005 tablets in teens with severe alopecia areata

  This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.

  Recruiting Phase 1 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07762443

• VC005 tablets in severe alopecia areata

  This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.

  Recruiting Phase 2 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07749716

• Ritlecitinib for patchy hair loss in teens and adults with alopecia areata

  This study tests whether ritlecitinib can help people 12 and older with patchy alopecia areata who have had symptoms for 6 months to 10 years.

  Recruiting at 30 sites Phase 3 Pfizer · Encinitas, California and 37 other locations · NCT07733765

• Alopecia Areata: looking at ferroptosis markers in blood

  This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Cerrahpasa Mahallesi · NCT07733063

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.